TLDR
- INTS stock soars 182% after breakthrough cancer trial results hit The Lancet
- INT230-6 shows strong tumor response and survival in late-stage cancer patients
- New data from Intensity Therapeutics sparks major shift in biotech market outlook
- Phase 1/2 trial of INT230-6 delivers hope for hard-to-treat solid tumors
- Lancet publication fuels INTS rally with data on immune-boosting cancer therapy
The stock of INTS surged 182.98% in early trading, hitting $0.7679 at 9:31 AM EDT.
Intensity Therapeutics, Inc. (INTS)
This sharp rally followed the release of groundbreaking clinical data published by The Lancet’s eBioMedicine journal. The report highlighted promising results for INT230-6 in treating advanced metastatic solid tumors.
Breakthrough Trial Data Drives Intensity Therapeutics, Inc. Stock Surge
INTS disclosed clinical findings from its IT-01 Phase 1/2 study on INT230-6. The publication in eBioMedicine detailed safety and efficacy outcomes in patients with refractory or metastatic cancers. The trial enrolled heavily pretreated patients across more than 20 cancer types.
The trial showed a disease control rate of 75% and a median overall survival (mOS) of 11.9 months. This result significantly outperforms historical averages of 4 to 7 months for similar phase 1/2 studies. Notably, a metastatic sarcoma subgroup recorded an mOS of 21.3 months using INT230-6 alone.
Dosing data revealed improved outcomes in patients receiving treatment volumes over 40% of their total tumor burden. Those patients achieved an 83.3% disease control rate and mOS of 18.7 months. The control group with lower dosing had only a 50% rate and mOS of 3.1 months.
INT230-6 Demonstrates Immune Activation and Tumor-Specific Drug Retention
INT230-6 is a novel intratumoral therapy developed by INTS using its proprietary drug-conjugation platform. The mechanism relies on local diffusion of cytotoxic agents directly into tumor sites after injection. Pharmacokinetic studies confirmed over 95% of the active agents remained within the tumor.
Clinical observations showed reduced tumor cell proliferation and increased immune cell activation in treated regions. Activated CD4+ and CD8+ T cells infiltrated the tumor microenvironment in most cases. In 20% of high-dose patients, uninjected tumors also shrank, showing possible systemic immune responses.
These effects, known as abscopal responses, are rarely observed with local treatments. The company attributed these responses to INT230-6’s design and delivery method. No grade 4 or 5 treatment-related toxicities were reported among the 64 patients.
Intensity Therapeutics, Inc. Advances Toward Phase 3 Development
INTS confirmed the start of randomized controlled studies. These include a Phase 3 trial in metastatic sarcoma under NCT06263231. The company intends to explore broader clinical applications across multiple solid tumor types.
The company emphasized the ability of INT230-6 to produce immunological tumor cell death, even in “cold” cancers. Such tumors typically respond poorly to immunotherapies or systemic treatments. INT230-6 may offer a new pathway for patients with limited options.
A public webcast featuring two lead authors from USC will be held on October 31, 2025. The presentation will outline the detailed study results and future development strategies. INTS continues to gain attention following its latest breakthrough.
This momentum positions INTS for a pivotal phase in its clinical journey. As more data emerges, the company’s pipeline could reshape cancer treatment paradigms. The stock reaction reflects strong confidence in its new therapeutic direction.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
